Publications by authors named "I Alarcon"
Long-term efficacy and safety of secukinumab in patients with moderate-to-severe hidradenitis suppurativa: Week 104 results from the SUNSHINE and SUNRISE extension trial.
Alexa B Kimball Falk G Bechara Aysha Badat Evangelos J Giamarellos-Bourboulis Alice B Gottlieb Ivette Alarcon
Br J Dermatol
November 2024
Background: SUNSHINE and SUNRISE demonstrated sustained clinical efficacy of secukinumab in patients with moderate-to-severe hidradenitis suppurativa (HS) through 52 weeks. Patients completing the core trials could enter a 4-year extension trial.
Objectives: To evaluate the long-term efficacy, safety/tolerability, and maintenance of clinical response of secukinumab through Week 104 in the extension trial.
Article Synopsis
- * General practitioners (GPs) play a crucial role in diagnosing HS, recognizing its symptoms, and managing associated health issues or comorbidities.
- * The review provides insights into the current landscape of HS treatments, specifically highlighting three approved biologics—adalimumab, secukinumab, and bimekizumab—and their implications for everyday clinical practice.
Article Synopsis
- This article discusses the diagnostic difficulties faced by primary health care providers when dealing with palmoplantar dermatoses (PPD), which are common skin conditions affecting the palms and soles.
- PPD can vary greatly in symptoms and types, being classified as infectious, non-infectious inflammatory, or hereditary, although specific conditions like palmoplantar pustulosis and dyshidrosis are highlighted.
- The article emphasizes the need for primary health care professionals to be knowledgeable about these conditions and suggests a diagnostic algorithm to help in their management and proper referrals.